Skip to main content
Log in

Evaluation of persistence of ductus venosus with Tc-99m DTPA galactosyl human serum albumin liver scintigraphy and I-123 iodoamphetamine per-rectal portal scintigraphy

  • Case Reports
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Tc-99m DTPA galaetosyl human serum albumin (Tc-99m GSA) hepatie seintigraphy was performed in two patients with patent ductus venosus before and after operation. To evaluate the portosystemic shunt flow, per-reatal portal scintigraphy with I-123 N-isopropyl-p-iodoamphetamine (IMP) was undergone in the same period. The portosystemic shunt indices (PSS index) were decreased from 67.9% to 7.3% in the patient 1, and from 77.3% to 22.7% in the patient 2, respectively. Quantitative indices of Tc-99m GSA hepatic scintigraphy improved dramatically in both patients. Under microscopic examination, nearly all the hepatic cells showed signs of severe fatty degeneration. After the operation, the severe fatty degeneration was alleviated and all the hepatic cells appeared normal. I-123 IMP per-rectal portal scintigraphy and Tc-99m GSA hepatic scintigraphy were useful in evaluating the quantitative shunt flow of the persistent ductus venosus and its hepatic functional reserve.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Loberant N, Barak M, Gaitini D, Herskovits M, Ben-Elisha M, Roguin N. closure of the ductus venosus in neonates: findings on real-time gray-scale, color-flow Doppler, and duplex Doppler sonography.AJR 159: 1083–1085, 1992.

    CAS  PubMed  Google Scholar 

  2. Adams FH. Fetal circulation and alteration at birth.In: Moss AJ, Adams FH, Emmanouilides GC. Heart disease in infants, children and adolescents, 2nd edn. Williams and Wilkins Co., Baltimore, pp. 11–17, 1978.

    Google Scholar 

  3. Barksy MF, Rankin RN, Wall WJ, Ghent CN, Garcia B. Patent ductus venosus: problems in assessment and management.Can J Surg 32: 271–275, 1989.

    Google Scholar 

  4. Ohnishi K, Hatano H, Nakayama T, Kohno K, Okuda K. An unusual portal-systemic shunt, most likely through a patient ductus venosus. A case report.Gastroenterology 85: 962–965, 1983.

    CAS  PubMed  Google Scholar 

  5. Mitchell IM, Pollock JC, Gibson AA. Patent ductus venosus.Pediatr Cardiol 12: 181–183, 1991.

    Article  CAS  PubMed  Google Scholar 

  6. Uchino T, Endo F, Ikeda S, Shiraki K, Sera Y, Matsuda I. Three brothers with progressive hepatic dysfunction and severe hepatic steatosis due to a patient ductus venosus.Gastroenterology 110: 1964–1968, 1996.

    Article  CAS  PubMed  Google Scholar 

  7. Shimomura T, Tomiguchi S, Kojima A, Hara M, Nakashima R, Gyama Y, et al. I-ISS IMP per-rectal portal seintigraphy for evaluation of the portal hemodynamics after hepatic embolization.Kumamoto Medical Journal 44 (3): 77–90, 1993.

    Google Scholar 

  8. Maisawa S, Takasago Y, Oyake Y, Maeta H, Pujiwara T. Patent ductus venosus with hypoplastic right hepatoportal system in a young child born with asymmetric intra-uterine growth retardation.Eur J Pediatr 151: 569–571, 1992.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kira, T., Ikeda, S., Sera, Y. et al. Evaluation of persistence of ductus venosus with Tc-99m DTPA galactosyl human serum albumin liver scintigraphy and I-123 iodoamphetamine per-rectal portal scintigraphy. Ann Nucl Med 14, 213–216 (2000). https://doi.org/10.1007/BF02987862

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02987862

Key words

Navigation